Skip to main content
NCBI home page
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1984 Apr;140(4):575–582.

Malignant or Accelarated Hypertension

N D Vaziri
PMCID: PMC1021775  PMID: 6372248

Abstract

Malignant or accelarated hypertension is a life-threatening medical emergency that is a possible complication of practically any hypertensive disorder. If not promptly treated it can cause severe, rapidly progressive target-organ damage and death. While the histo-pathologic features of malignant hypertension are well recognized, the pathogenesis of the associated vascular lesions and the transition from a benign to a malignant phase are unclear. With adequate control of hypertension, progression to the accelarated or malignant phase can be prevented. Moreover, promptly and effectively reducing the blood pressure during the malignant phase can prevent, minimize or even reverse serious target organ injury. Malignant hypertension, therefore, is both preventable and treatable.

Full text

PDF
575

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ASSCHER A. W., ANSON S. G. A vascular permeability factor of renal origin. Nature. 1963 Jun 15;198:1097–1098. doi: 10.1038/1981097a0. [DOI] [PubMed] [Google Scholar]
  2. Allison P. R., Bleehan N., Brown W., Pickering G. W., Robb-Smith A. H., Russell R. P. The production and resolution of hypertensive vascular lesions in the rabbit. Clin Sci. 1967 Aug;33(1):39–51. [PubMed] [Google Scholar]
  3. Aloia J. F., Beutow G. Malignant hypertension with aldosteronoma producing adenoma. Am J Med Sci. 1974 Oct;268(4):241–245. doi: 10.1097/00000441-197410000-00005. [DOI] [PubMed] [Google Scholar]
  4. Anderson R. J., Hart G. R., Crumpler C. P., Reed W. G., Matthews C. A. Oral clonidine loading in hypertensive urgencies. JAMA. 1981 Aug 21;246(8):848–850. [PubMed] [Google Scholar]
  5. BRAIN M. C., DACIE J. V., HOURIHANE D. O. Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis. Br J Haematol. 1962 Oct;8:358–374. doi: 10.1111/j.1365-2141.1962.tb06541.x. [DOI] [PubMed] [Google Scholar]
  6. Baglin A., Weiss Y., Safar M., Milliez P. Hyperaldostéronisme primaire avec hypertension maligne. Nouv Presse Med. 1973 Feb 3;2(5):295–297. [PubMed] [Google Scholar]
  7. Beevers D. G., Brown J. J., Ferriss J. B., Fraser R., Lever A. F., Robertson J. I., Tree M. Renal abnormalities and vascular complications in primary hyperaldosteronism. Evidence on tertiary hyperaldosteronism. Q J Med. 1976 Jul;45(179):401–410. [PubMed] [Google Scholar]
  8. Brain M. C., Baker L. R., McBride J. A., Rubenberg M. L., Dacie J. V. Treatment of patients with microangiopathic haemolytic anaemia with heparin. Br J Haematol. 1968 Dec;15(6):603–621. doi: 10.1111/j.1365-2141.1968.tb01582.x. [DOI] [PubMed] [Google Scholar]
  9. Brunner H. R., Kirshman J. D., Sealey J. E., Laragh J. H. Hypertension of renal origin: evidence for two different mechanisms. Science. 1971 Dec 24;174(4016):1344–1346. doi: 10.1126/science.174.4016.1344. [DOI] [PubMed] [Google Scholar]
  10. Burkholder P. M. Malignant nephrosclerosis. Arch Pathol. 1965 Dec;80(6):583–589. [PubMed] [Google Scholar]
  11. Catt K. J., Cran E., Zimmet P. Z., Best J. B., Cain M. D., Coghlan J. P. Angiotensin II blood-levels in human hypertension. Lancet. 1971 Mar 6;1(7697):459–464. doi: 10.1016/s0140-6736(71)91085-3. [DOI] [PubMed] [Google Scholar]
  12. Click R. L., Joyner W. L., Gilmore J. P. Reactivity of gomerular afferent and efferent arterioles in renal hypertension. Kidney Int. 1979 Feb;15(2):109–115. doi: 10.1038/ki.1979.16. [DOI] [PubMed] [Google Scholar]
  13. Cohen I. M., Katz M. A. Oral clonidine loading for rapid control of hypertension. Clin Pharmacol Ther. 1978 Jul;24(1):11–15. doi: 10.1002/cpt197824111. [DOI] [PubMed] [Google Scholar]
  14. Cordingley F. T., Jones N. F., Wing A. J., Hilton P. J. Reversible renal failure in malignant hypertension. Clin Nephrol. 1980 Aug;14(2):98–103. [PubMed] [Google Scholar]
  15. Dauda G., Möhring J., Hofbauer K. G., Homsy E., Miksche U., Orth H., Gross F. The vicious circle in acute malignant hypertension of rats. Clin Sci Mol Med Suppl. 1973 Aug;45 (Suppl 1):251s–2515. doi: 10.1042/cs045251s. [DOI] [PubMed] [Google Scholar]
  16. Del Greco F., Dolkart R., Skom J., Method H. Association of accelerated (malignant) hypertension in a patient with primary aldosteronism. J Clin Endocrinol Metab. 1966 Aug;26(8):808–814. doi: 10.1210/jcem-26-8-808. [DOI] [PubMed] [Google Scholar]
  17. Dunn F. G., Jones J. V., Fife R. Malignant hypertension associated with use of oral contraceptives. Br Heart J. 1975 Mar;37(3):336–338. doi: 10.1136/hrt.37.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. FISHER E. R., RODNAN G. P. Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol. 1958 Jan;65(1):29–39. [PubMed] [Google Scholar]
  19. FLOYER M. A. The effect of nephrectomy and adrenalectomy upon the blood pressure in hypertensive and normotensive rats. Clin Sci. 1951 Nov;10(4):405–421. [PubMed] [Google Scholar]
  20. Finnerty F. A., Jr Hypertensive crisis. JAMA. 1974 Sep 9;229(11):1479–1480. [PubMed] [Google Scholar]
  21. GIESE J. ACUTE HYPERTENSIVE VASCULAR DISEASE. 1. RELATION BETWEEN BLOOD PRESSURE CHANGES AND VASCULAR LESIONS IN DIFFERENT FORMS OF ACUTE HYPERTENSION. Acta Pathol Microbiol Scand. 1964;62:481–496. doi: 10.1111/apm.1964.62.4.481. [DOI] [PubMed] [Google Scholar]
  22. GIESE J. PATHOGENESIS OF VASCULAR DISEASES CAUSED BY ACUTE RENAL ISCHAEMIA. Acta Pathol Microbiol Scand. 1963;59:417–427. doi: 10.1111/j.1699-0463.1963.tb01241.x. [DOI] [PubMed] [Google Scholar]
  23. Gavras H., Brown W. C., Brown J. J., Lever A. F., Linton A. L., MacAdam R. F., McNicol G. P., Robertson J. I., Wardrop C. Microangipathic hemolytic anemia and the development of the malignant phase of hypertension. Circ Res. 1971 May;28(5 Suppl):127–142. doi: 10.1161/01.res.28.5.ii-127. [DOI] [PubMed] [Google Scholar]
  24. George J. M., Wright L., Bell N. H., Bartter F. C. The syndrome of primary aldosteronism. Am J Med. 1970 Mar;48(3):343–356. doi: 10.1016/0002-9343(70)90065-3. [DOI] [PubMed] [Google Scholar]
  25. Goldby F. S., Beilin L. J. How an acute rise in arterial pressure damages arterioles. Electron microscopic changes during angiotensin infusion. Cardiovasc Res. 1972 Sep;6(5):569–584. doi: 10.1093/cvr/6.5.569. [DOI] [PubMed] [Google Scholar]
  26. Gross F. Niere und Hochdruck. Klin Wochenschr. 1972 Jul 1;50(13):621–635. doi: 10.1007/BF01487077. [DOI] [PubMed] [Google Scholar]
  27. Gross F. The renin-angiotensin system and hypertension. Ann Intern Med. 1971 Nov;75(5):777–787. doi: 10.7326/0003-4819-75-5-777. [DOI] [PubMed] [Google Scholar]
  28. HARINGTON M., KINCAID-SMITH P., McMICHAEL J. Results of treatment in malignant hypertension: a seven-year experience in 94 cases. Br Med J. 1959 Nov 14;2(5158):969–980. doi: 10.1136/bmj.2.5158.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. HEPTINSTALL R. H. Renal biopsies in hypertension. Br Heart J. 1954 Apr;16(2):133–141. doi: 10.1136/hrt.16.2.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. HERBERTSON B. M., KELLAWAY T. D. Arterial necrosis in the rat produced by methoxamine. J Pathol Bacteriol. 1960 Jul;80:87–92. doi: 10.1002/path.1700800111. [DOI] [PubMed] [Google Scholar]
  31. Harrison T. S., Birbari A., Seaton J. F. Malignant hypertension in pheochromocytoma: correlation with plasma renin activity. Johns Hopkins Med J. 1972 May;130(5):329–332. [PubMed] [Google Scholar]
  32. Hoyer J. R., Michael A. F., Hoyer L. W. Immunofluorescent localization of antihemophilic factor antigen and fibrinogen in human renal diseases. J Clin Invest. 1974 May;53(5):1375–1384. doi: 10.1172/JCI107686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. KAHN J. R., SKEGGS L. T., Jr, SHUMWAY N. P., WISENBAUGH P. E. The assay of hypertensin from the arterial blood of normotensive and hypertensive human beings. J Exp Med. 1952 Jun;95(6):523–529. doi: 10.1084/jem.95.6.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. KAPLAN N. M. PRIMARY ALDOSTERONISM WITH MALIGNANT HYPERTENSION. N Engl J Med. 1963 Dec 12;269:1282–1286. doi: 10.1056/NEJM196312122692403. [DOI] [PubMed] [Google Scholar]
  35. Kanada S. A., Kanada D. J., Hutchinson R. A., Wu D. Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med. 1976 Jun;84(6):696–699. doi: 10.7326/0003-4819-84-6-696. [DOI] [PubMed] [Google Scholar]
  36. Kaneda H., Yamauchi T., Murata T., Matsumoto J., Haruyama T. Treatment of malignant hypertension with infusion of sodium chloride; a case report and a review. Tohoku J Exp Med. 1980 Oct;132(2):179–186. doi: 10.1620/tjem.132.179. [DOI] [PubMed] [Google Scholar]
  37. Kincaid-Smith P., Hua A. S., Myers J. B., MacDonald I., Fang P. Prazosin and hydrallazine in the treatment of hypertension. Clin Sci Mol Med Suppl. 1976 Dec;3:617s–619s. doi: 10.1042/cs051617s. [DOI] [PubMed] [Google Scholar]
  38. Kincaid-Smith P., Laver M. C., Fairley K. F. Dipyridamole and anticoagulants in renal disease due to glomerular and vascular lesions. A new approach to therapy. Med J Aust. 1970 Jan 24;1(4):145–151. [PubMed] [Google Scholar]
  39. Kumar G. K., Dastoor F. C., Robayo J. R., Razzaque M. A. Side effects of diazoxide. JAMA. 1976 Jan 19;235(3):275–276. [PubMed] [Google Scholar]
  40. Ledingham J. G., Rajagopalan B. Cerebral complications in the treatment of accelerated hypertension. Q J Med. 1979 Jan;48(189):25–41. [PubMed] [Google Scholar]
  41. Lee D. B., Ehrlich R. M., Dabir-Vaziri N., Sambhi M. P., Doud R. B., Barajas L., Schultze R. G. Post-transplant hypertension. Normoreninemic severe hypertension treated by bilateral nephrectomies. Urology. 1977 Apr;9(4):425–428. doi: 10.1016/0090-4295(77)90222-9. [DOI] [PubMed] [Google Scholar]
  42. Linton A. L., Gavras H., Gleadle R. I., Hutchison H. E., Lawson D. H., Lever A. F., Macadam R. F., McNicol G. P., Robertson J. I. Microangiopathic haemolytic anaemia and the pathogenesis of malignant hypertension. Lancet. 1969 Jun 28;1(7609):1277–1282. doi: 10.1016/s0140-6736(69)92221-1. [DOI] [PubMed] [Google Scholar]
  43. MASSON G. M. C., PLAHL G., CORCORAN A. C., PAGE I. H. Accelerated hypertensive vascular disease from saline and renin in nephrectomized dogs. AMA Arch Pathol. 1953 Feb;55(2):85–97. [PubMed] [Google Scholar]
  44. McAllister R. G., Jr, Van Way C. W., 3rd, Dayani K., Anderson W. J., Temple E., Michelakis A. M., Coppage W. S., Jr, Oates J. A. Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res. 1971 May;28(5 Suppl):160–174. doi: 10.1161/01.res.28.5.ii-160. [DOI] [PubMed] [Google Scholar]
  45. McCORMACK L. J., BELAND J. E., SCHNECKLOTH R. E., CORCORAN A. C. Effects of antihypertensive treatment on the evolution of the renal lesions in malignant nephrosclerosis. Am J Pathol. 1958 Nov-Dec;34(6):1011–1021. [PMC free article] [PubMed] [Google Scholar]
  46. Medsger T. A., Jr, Masi A. T., Rodnan G. P., Benedek T. G., Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971 Sep;75(3):369–376. doi: 10.7326/0003-4819-75-3-369. [DOI] [PubMed] [Google Scholar]
  47. Medsger T. A., Jr, Masi A. T. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis. 1973 Oct;26(10):647–660. doi: 10.1016/0021-9681(73)90054-4. [DOI] [PubMed] [Google Scholar]
  48. Menard J., Meyer P., Milliez P. L'hypertension artérielle d'origine rénale: sécrétion inappropriée de rénine. Presse Med. 1967 Oct 14;75(42):2083–2085. [PubMed] [Google Scholar]
  49. Mizroch S., Yurasek M. Hypotension and bradycardia following diazoxide and hydralazine therapy. JAMA. 1977 Jun 6;237(23):2471–2472. doi: 10.1001/jama.1977.03270500023012. [DOI] [PubMed] [Google Scholar]
  50. Mroczek W. J. Malignant hypertension: kidneys too good to be extirpated. Ann Intern Med. 1974 Jun;80(6):754–757. doi: 10.7326/0003-4819-80-6-754. [DOI] [PubMed] [Google Scholar]
  51. Möhring J., Petri M., Szokol M., Haack D., Möhring B. Effects of saline drinking on malignant course of renal hypertension in rats. Am J Physiol. 1976 Mar;230(3):849–857. doi: 10.1152/ajplegacy.1976.230.3.849. [DOI] [PubMed] [Google Scholar]
  52. OLD J. W., RUSSELL W. O. Necrotizing pulmonary arteritis occurring with congenital heart disease (Eisenmenger complex); report of case with necropsy. Am J Pathol. 1950 Sep;26(5):789–805. [PMC free article] [PubMed] [Google Scholar]
  53. Oldershaw P. J., Edmondson R. P. Renal tuberculosis presenting with accelerated hypertension. Tubercle. 1978 Sep;59(3):197–199. doi: 10.1016/0041-3879(78)90027-2. [DOI] [PubMed] [Google Scholar]
  54. PARONETTO F. IMMUNOCYTOCHEMICAL OBSERVATIONS ON THE VASCULAR NECROSIS AND RENAL GLOMERULAR LESIONS OF MALIGNANT NEPHROSCLEROSIS. Am J Pathol. 1965 Jun;46:901–915. [PMC free article] [PubMed] [Google Scholar]
  55. PERERA G. A. The accelerated form of hypertension: a unique entity. Trans Assoc Am Physicians. 1958;71:62–68. [PubMed] [Google Scholar]
  56. Padfield P. L., Morton J. J. Proceedings: Application of a sensitive radioimmunoassay for plasma arginine vasopressin to pathological conditions in man. Clin Sci Mol Med. 1974 Sep;47(3):16P–17P. doi: 10.1042/cs047016pb. [DOI] [PubMed] [Google Scholar]
  57. Perry H. M., Jr, Schroeder H. A., Catanzaro F. J., Moore-Jones D., Camel G. H. Studies on the control of hypertension. 8. Mortality, morbidity, and remissions during twelve years of intensive therapy. Circulation. 1966 Jun;33(6):958–972. doi: 10.1161/01.cir.33.6.958. [DOI] [PubMed] [Google Scholar]
  58. Pickering G. Reversibility of malignant hypertension. Follow-up of three cases. Lancet. 1971 Feb 27;1(7696):413–418. doi: 10.1016/s0140-6736(71)92411-1. [DOI] [PubMed] [Google Scholar]
  59. RODNAN G. P., SCHREINER G. E., BLACK R. L. Renal involvement in progressive systemic sclerosis (generalized scleroderma). Am J Med. 1957 Sep;23(3):445–462. doi: 10.1016/0002-9343(57)90324-8. [DOI] [PubMed] [Google Scholar]
  60. Ram C. V., Kaplan N. M. Individual titration of diazoxide dosage in the treatment of severe hypertension. Am J Cardiol. 1979 Mar;43(3):627–630. doi: 10.1016/0002-9149(79)90023-7. [DOI] [PubMed] [Google Scholar]
  61. Razzak I. A., Bauer W., Itzel W. Hepatitis-B-antigenemia with panarteritis, diffuse proliferative glomerulitis and malignant hypertension. Am J Gastroenterol. 1975 Jun;63(6):476–480. [PubMed] [Google Scholar]
  62. Robertson A. L., Khairallah P. A. Effects of angiotensin II and some analogues on vascular permeability in the rabbit. Circ Res. 1972 Dec;31(6):923–931. doi: 10.1161/01.res.31.6.923. [DOI] [PubMed] [Google Scholar]
  63. SCHOTTSTAEDT M. F., SOKOLOW M. The natural history and course of hypertension with papilledema (malignant hypertension). Am Heart J. 1953 Mar;45(3):331–362. doi: 10.1016/0002-8703(53)90147-1. [DOI] [PubMed] [Google Scholar]
  64. SWORN B. R. Total cystectomy. Br Med J. 1949 Feb 5;1(4596):221–223. doi: 10.1136/bmj.1.4596.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. SYMMERS W. S. C. Necrotizing pulmonary arteriopathy associated with pulmonary hypertension. J Clin Pathol. 1952 Feb;5(1):36–41. doi: 10.1136/jcp.5.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Simon N. M., Graham M. B., Kyser F. A., Gashti E. N. Resolution of renal failure with malignant hypertension in scleroderma. Case report and review of the literature. Am J Med. 1979 Sep;67(3):533–539. doi: 10.1016/0002-9343(79)90807-6. [DOI] [PubMed] [Google Scholar]
  67. Spargo B. H., Ordóez N. G., Ringus J. C. The differential diagnosis of crescentic glomerulonephritis. The pathology of specific lesions with prognostic implications. Hum Pathol. 1977 Mar;8(2):187–204. doi: 10.1016/s0046-8177(77)80080-4. [DOI] [PubMed] [Google Scholar]
  68. Spitalewitz S., Porush J. G., Oguagha C. Use of oral clonidine for rapid titration of blood pressure in severe hypertension. Chest. 1983 Feb;83(2 Suppl):404–407. doi: 10.1378/chest.83.2_supplement.404. [DOI] [PubMed] [Google Scholar]
  69. Strandgaard S., Olesen J., Skinhoj E., Lassen N. A. Autoregulation of brain circulation in severe arterial hypertension. Br Med J. 1973 Mar 3;1(5852):507–510. doi: 10.1136/bmj.1.5852.507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Thien T. A., Huysmans F. T., Gerlag P. G., Koene R. A., Wijdeveld P. G. Diazoxide infusion in severe hypertension and hypertensive crisis. Clin Pharmacol Ther. 1979 Jun;25(6):795–799. doi: 10.1002/cpt1979256795. [DOI] [PubMed] [Google Scholar]
  71. Thomas R. D., Lee M. R. Sodium repletion and beta-adrenergic blockade in treatment of salt depletion with accelerated hypertension. Br Med J. 1976 Dec 11;2(6049):1425–1426. doi: 10.1136/bmj.2.6049.1425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  72. Woods J. W., Blythe W. B., Huffines W. D. Management of malignant hypertension complicated by renal insufficiency. A follow-up study. N Engl J Med. 1974 Jul 4;291(1):10–14. doi: 10.1056/NEJM197407042910103. [DOI] [PubMed] [Google Scholar]
  73. Zacherle B. J., Richardson J. A. Irreversible renal failure secondary to hypertension induced by oral contraceptives. Ann Intern Med. 1972 Jul;77(1):83–85. doi: 10.7326/0003-4819-77-1-83. [DOI] [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES